Dark

ADMP
Adamis Pharmaceuticals Corporation
stock NASDAQ

Inactive

Sep 7, 2023

0.7751USD+0.854%(+0.0066)119,837

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-0.77)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 10, 2022

07:38AM EST Adamis Pharmaceuticals Submits Fast Track Application To FDA For Tempol For Treatment And Prevention Of COVID-19 Benzinga

07:30AM EST Adamis Pharmaceuticals Submits Fast Track Application to FDA for GlobeNewswire Inc

Dec 1, 2021

07:30AM EST Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data GlobeNewswire Inc

Nov 23, 2021

02:41PM EST Adamis Pharmaceuticals Says Regains Compliance With NASDAQ Continued Listing Requirements Benzinga

02:40PM EST Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued GlobeNewswire Inc

Nov 22, 2021

05:00PM EST Adamis Pharmaceuticals Sales For 9 Months Ended Sept. 30, 2021 $3.4M Benzinga

04:48PM EST Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the nine months ended September 30, 2021 and provided a business update. GlobeNewswire Inc

03:54AM EST Earnings Scheduled For November 22, 2021 Benzinga

Nov 21, 2021

03:05PM EST The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week Benzinga

Nov 19, 2021

03:34PM EST Adamis Pharmaceuticals Schedules Financial Results Conference Call GlobeNewswire Inc

Oct 18, 2021

08:27AM EDT Adamis Pharmaceuticals Corporation (ADMP) announced the FDA has approved ZIMHI 5 mg/0.5 mL, a high-dose naloxone injection for use in the treatment of opioid overdose. The company is preparing for the full commercial launch of ZIMHI in the first quarter of 2022. RTTNews

08:16AM EDT Adamis Receives FDA Approval For ZIMHI For The Treatment Of Opioid Overdose RTTNews

07:30AM EDT Adamis Receives FDA Approval For ZIMHI Benzinga

07:30AM EDT Adamis Pharmaceuticals Corporation(Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis ZIMHI (naloxone HCL Injection, USP) 5 mg/0.5 mL product. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose. GlobeNewswire Inc

Oct 4, 2021

07:30AM EDT Adamis Pharmaceuticals Corporation(Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the companys board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective October 1, 2021. GlobeNewswire Inc

Sep 2, 2021

07:30AM EDT Adamis Pharmaceuticals Doses First Patients In Phase 2/3 Clinical Trial For Tempol In The Treatment Of COVID-19 Benzinga

07:30AM EDT Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical GlobeNewswire Inc

Aug 24, 2021

04:06PM EDT Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer Benzinga

04:05PM EDT Adamis Announces Appointment of David C. Benedicto as Chief GlobeNewswire Inc

01:14PM EDT Immunology Journal Publishes Data For Adamis' COVID-19 Candidate Benzinga

07:31AM EDT Adamis Pharmaceuticals Highlights Publication With The Human Immune Monitoring Center At Stanford Demonstrating Tempol 'Significantly Inhibited Multiple Cytokines from COVID-19 Patient's Cells' Benzinga

07:30AM EDT Tempol: A potential home treatment for COVID-19 ( https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19). Trial to begin shortly. GlobeNewswire Inc

Aug 19, 2021

12:20PM EDT Mid-Day Market Update: Macy's Jumps After Q2 Results; PharmaCyte Biotech Shares Drop Benzinga

07:32AM EDT Adamis Pharmaceuticals Highlights NIH Article 'Tempol: A Potential Home Treatment for COVID-19' Benzinga

07:30AM EDT Adamis Highlights National Institutes of Health (NIH) Article GlobeNewswire Inc

Aug 16, 2021

05:49PM EDT Pingtan Marine Enterprise, Adamis Pharma, Celularity, Carver Bancorp File For Non-Timely 10-Q Benzinga

05:34PM EDT 13F From David Einhorn's Greenlight Shows New Stake In Adamis Pharma Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

05:19PM EDT Adamis Pharma Reports Deal To Sell Portion Of US Compounding Business, No Terms Disclosed Benzinga

04:05PM EDT Adamis Announces Agreement to Sell Portion of US Compounding Business GlobeNewswire Inc

Jul 19, 2021

04:05PM EDT Adamis Announces Results of 2021 Annual Meeting of Stockholders Business Wire

Jul 13, 2021

08:21AM EDT Adamis Urges Stockholders To Vote To Reelect The Company's Board Of Directors At Upcoming Annual Meeting On July 16 RTTNews

08:00AM EDT Adamis Urges Stockholders to Vote to Reelect the Company's Board of Directors at Upcoming Annual Meeting on Friday, July 16th Business Wire

Jul 1, 2021

08:13AM EDT Adamis Pharma Sends Letter To Shareholders, Addresses Jerald Hammann's 'Costly, Distracting, Misguided' Campaign Benzinga

08:00AM EDT Adamis Sends Letter to Stockholders to Address Jerald A. Hammann's Costly, Distracting and Misguided Campaign Business Wire

Jun 30, 2021

06:00AM EDT Adamis Pharma Received FDA Approval on Labeling for Symjepi 0.3MG/0.3ML (0.3MG/0.3ML); 0.15MG/0.3ML (0.15MG/0.3ML) Benzinga

Jun 29, 2021

09:31AM EDT Adamis Pharma US Patent & Trademark Office Abstract For Co.'s 'Drug compositions' Shows Patent Granted By US PTO Benzinga

Jun 28, 2021

07:10AM EDT Adamis Urges Stockholders To Vote To Re-elect All Five Members Of Board RTTNews

07:05AM EDT Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19; Urges Stockholders to Elect the Company's Highly-Qualified Directors at the July 16th Annual Meeting Benzinga

07:00AM EDT Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19 Business Wire

Jun 14, 2021

09:10AM EDT Adamis Urges Stockholders To Vote On WHITE Proxy Card To Re-elect All Five Members Of Board RTTNews

09:00AM EDT Adamis Files Definitive Proxy Statement and Sends Letter to Stockholders Business Wire

Jun 11, 2021

07:59AM EDT Adamis Pharmaceuticals Corp. (ADMP) said Friday that clinical trial start-up activities are underway for examining the effects of its experimental drug, Tempol, in the treatment of COVID-19. The company is carrying out the activities with a large clinical research organization. RTTNews

07:36AM EDT Adamis Says Clinical Trial Start-up Activities Are Underway For Examining Effects Of Tempol RTTNews

07:32AM EDT Adamis Pharma Offers Update On Clinical Trial Start-Up Progress For Tempol In Treatment Of COVID-19 Benzinga

07:30AM EDT Adamis Pharmaceuticals Corporation(NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of Tempol, which is the Companys experimental drug, in the treatment of COVID-19. Adamis is carrying out these activities with a large clinical research organization (CRO). GlobeNewswire Inc

Jun 9, 2021

08:37AM EDT Adamis Pharma Stock Jumps After Naloxone Injection Under FDA Review For Opioid Overdose Benzinga

07:34AM EDT Adamis Announces FDA Has Has Accepted For Review Co.'s Resubmitted NDA For ZIMHI Benzinga

07:30AM EDT Adamis Provides Update on ZIMHI GlobeNewswire Inc

Jun 7, 2021

09:51AM EDT Adamis Pharma Stock Jumps as NIH Sees Promise in Tempol for COVID-19 Benzinga

07:32AM EDT Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19 Benzinga

07:30AM EDT NIH Researchers Contend Tempol may be a Promising Oral Antiviral Treatment for COVID-19 GlobeNewswire Inc

Jun 3, 2021

04:15PM EDT Raymond James Says NIH Study Of Adamis Pharmaceuticals' TEMPOL Is 's a significant external validation of TEMPOL's potential to play a role in the treatment of COVID-19' Benzinga

Jun 1, 2021

07:43AM EDT Adamis Provides Business Update; Says NDA For ZIMHI Submitted To FDA RTTNews

07:38AM EDT Adamis Pharmaceuticals Preparing To Begin Patient Enrollment In A Phase 2/3 Clinical Trial To Evaluate Use Of Tempol In Patients With COVID-19 Benzinga

07:30AM EDT Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today provided the following business update. GlobeNewswire Inc

May 28, 2021

04:04PM EDT Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from GlobeNewswire Inc

May 17, 2021

04:05PM EDT Adamis Pharmaceuticals Provides Update on First Quarter 2021 GlobeNewswire Inc

09:32AM EDT Adamis Pharma Stock Gains On Resubmission Of Zimhi US Application For Opioid Overdose Benzinga

07:36AM EDT Adamis Resubmits ZIMHI NDA To FDA For Treatment Of Opioid Overdose RTTNews

07:31AM EDT Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application To FDA For Treatment Of Opioid Overdose Benzinga

07:30AM EDT Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For May 17, 2021 Benzinga

May 12, 2021

07:30AM EDT Adamis Pharmaceuticals Schedules First Quarter 2021 Financial GlobeNewswire Inc

Apr 15, 2021

04:41PM EDT Adamis Pharmaceuticals Issue FY20 Sales $16.5M Down From $22.1M YoY Benzinga

04:40PM EDT Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 GlobeNewswire Inc

07:49AM EDT The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split Benzinga

04:13AM EDT Earnings Scheduled For April 15, 2021 Benzinga

Apr 13, 2021

04:03PM EDT Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 GlobeNewswire Inc

Apr 12, 2021

10:28AM EDT Adamis Pharma To Resubmit Zimhi US Application For Opioid Overdose Soon Benzinga

08:22AM EDT Adamis To Resubmit NDA For ZIMHI Within 45 Days - Quick Facts RTTNews

07:26AM EDT Adamis Plans To Resubmit NDA For ZIMHI To FDA Within Next 45 Days RTTNews

07:06AM EDT Adamis Pharmaceuticals Says Believes Typa A Meeting With FDA For ZIMHI In Response To Complete Response Letter Was 'Productive' And Says Plans NDA Resubmission Within Next 45 Days Benzinga

07:00AM EDT Adamis Pharmaceuticals Provides an Update on ZIMHI GlobeNewswire Inc

Mar 15, 2021

10:05AM EDT Adamis Pharma's Tempol Decreases COVID-19 Related Lung Inflammation In Animal Studies Benzinga

09:00AM EDT Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation GlobeNewswire Inc

Feb 22, 2021

09:00AM EST Adampis Pharmaceuticals Says Cleared To Proceed With Human Studies Of Tempol For Treatment Of COVID-19 Benzinga

09:00AM EST Adamis Pharmaceuticals Cleared to Proceed with Human Studies of GlobeNewswire Inc

Feb 17, 2021

12:03PM EST Adamis Pharma Shares Fall Despite US Patent Covering Naloxone Benzinga

12:01PM EST Adamis Pharma Stock Down Despite US Patent Covering Naloxone Benzinga

09:04AM EST Adamis Pharmaceuticals Says Received Notice That One Patent Application Relating To ZIMHI Was Allowed By U.S. Patent And Trademark Office Benzinga

09:00AM EST Adamis Pharmaceuticals Strengthens Patent Portfolio for Its GlobeNewswire Inc

Feb 16, 2021

03:04PM EST 'PATENT $ADMP Adamis Pharmaceuticals issued US Patent No. 10,919,011 today by the US Patent and Trademark Office, titled: POWDER MIXING APPARATUS AND METHOD OF USE.' - Patent Eagle Benzinga

Feb 4, 2021

09:09AM EST Adamis Pharmaceuticals Received Notice Of Allowance On 1/28 For US Patent Application Titled 'DRY POWDER INHALER DOSE COUNTERS' Benzinga

Feb 2, 2021

04:05PM EST Adamis Pharmaceuticals Announces Closing of Public Offering of GlobeNewswire Inc

Jan 29, 2021

09:02AM EST Adamis Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock At $1.11/Share Benzinga

09:00AM EST Adamis Pharmaceuticals Announces Pricing of Public Offering of GlobeNewswire Inc

07:45AM EST The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO Benzinga

Jan 28, 2021

04:01PM EST Adamis Pharma Reports Offering Of Common Stock, No Size Disclosed Benzinga

09:01AM EST Adamis Pharmaceuticals And Human Immune Monitoring Center At Stanford University Announce Preliminary Tempol Data In Cells From COVID-19 Patients Benzinga

09:00AM EST Adamis Pharmaceuticals and Human Immune Monitoring Center at GlobeNewswire Inc

Jan 26, 2021

09:05AM EST Adamis Pharmaceuticals Announces Co Entered Into Non-Binding Letter Of Intent With Potential Buyer For Sale Of Substantially All Assets Of U.S. Compounding Subsidiary Benzinga

09:00AM EST Adamis Pharmaceuticals Provides Update On Its US Compounding Business GlobeNewswire Inc

Jan 25, 2021

08:45AM EST Immunotherapy Using Immune-Checkpoint Inhibitors (ICI) Modulators Are PR Newswire

Jan 22, 2021

02:30PM EST Mid-Afternoon Market Update: Dow Falls 125 Points; Global Ship Lease Shares Plunge Benzinga

12:19PM EST Mid-Day Market Update: IBM Drops On Downbeat Revenue; Montauk Renewables Shares Surge Benzinga

Jan 21, 2021

04:08PM EST Adamis Pharmaceuticals Announces SYMJEPI Products Now Available In Walgreens Prescription Savings Club For $99.99 For A Two-Pack Benzinga

04:05PM EST SYMJEPI Products Now Available in the Walgreens Prescription GlobeNewswire Inc

10:02AM EST Looking Into Adamis Pharmaceuticals's Return On Capital Employed Benzinga

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 20, 2021

09:02AM EST Adamis Announces IND Submission To FDA For Tempol For Treatment Of COVID-19 RTTNews

09:02AM EST Adamis Pharmaceuticals Announces IND Submission To FDA For Tempol For Treatment Of COVID-19 Benzinga

09:00AM EST Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol GlobeNewswire Inc

Dec 1, 2020

09:18AM EST Adamis Intends To Address All Deficiencies Raised In ZIMHI CRL And Request FDA Approve NDA RTTNews

09:02AM EST Adamis Pharmaceuticals Announces Planned Response To FDA Complete Response Letter For ZIMHI Benzinga

09:00AM EST Adamis Pharmaceuticals Corporation(NASDAQ: ADMP) today announced a planned response to a Complete Response Letter (CRL) from theU.S. Food and Drug Administration(FDA), regarding its New Drug Application (NDA) for Adamis ZIMHI high dose naloxone injection product for the treatment of opioid overdose. GlobeNewswire Inc

Nov 28, 2020

01:08PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 16, 2020

11:55AM EST Why Adamis Pharmaceuticals Stock Is Trading Lower Today Benzinga

09:43AM EST CORRECTION: Adamis Pharmaceuticals Shares Are Trading Lower Benzinga

06:49AM EST Adamis Pharma Receives a Complete Response Letter From the FDA for its ZIMHI Benzinga

06:45AM EST Adamis Pharmaceuticals Receives a Complete Response Letter from GlobeNewswire Inc

Nov 9, 2020

04:55PM EST Adamis Pharmaceuticals Q3 Sales $4.30M Miss $6.98M Estimate Benzinga

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Oct 12, 2020

10:25AM EDT Looking Into Adamis Pharmaceuticals's Return On Capital Employed Benzinga

Sep 18, 2020

02:31PM EDT Mid-Afternoon Market Update: Dow Tumbles 300 Points; COMPASS Pathways Shares Spike Higher Benzinga

12:06PM EDT Mid-Day Market Update: Nasdaq Turns Lower; Westport Fuel Systems Shares Surge Benzinga

09:14AM EDT Adamis Prices Public Offering Of 16.13 Mln Shares At $0.62 Per Share RTTNews

09:02AM EDT Adamis Pharmaceuticals Announces Pricing Of Offering Of Common Stock At $0.62/Share Benzinga

09:00AM EDT Adamis Pharmaceuticals Announces Pricing of Public Offering of GlobeNewswire Inc

Sep 17, 2020

04:06PM EDT Adamis Pharmaceuticals Announces Proposed Public Offering Of Common Stock; Size Not Disclosed Benzinga

04:05PM EDT Adamis Pharmaceuticals Announces Proposed Public Offering of GlobeNewswire Inc

Sep 3, 2020

04:05PM EDT Adamis Pharmaceuticals Provides Update on Annual Meeting of GlobeNewswire Inc

Aug 18, 2020

09:37AM EDT Adamis Pharmaceuticals shares are trading lower after the company announced sales for the first six months of 2020 decreased by 20% compared to the comparable period of 2019. Benzinga

Aug 17, 2020

04:43PM EDT Adamis Pharmaceuticals Says Cash And Equivalents At End Of Q2 Were $7.9M Benzinga

04:40PM EDT Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2020 and provided a business update. GlobeNewswire Inc

Aug 14, 2020

09:09AM EDT Adamis Reports Pre-IND Feedback From FDA Enabling Advancement Of Tempol RTTNews

09:05AM EDT Adamis Says FDA Pre-IND Feedback For Tempol Allows Co. 'to proceed to the next step of formally submitting an IND for Tempol' And 'begin formal applications for funding to governmental agencies to support the clinical trial and large-scale manufacturing' Benzinga

09:00AM EDT Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA GlobeNewswire Inc

Aug 5, 2020

04:05PM EDT Adamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid GlobeNewswire Inc

Jul 17, 2020

05:08AM EDT 64 Biggest Movers From Yesterday Benzinga